Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
Recursion Pharmaceuticals, Inc. (RXRX) Q1 2026 Earnings Call Transcript
07:51pm, Wednesday, 06'th May 2026
Recursion Pharmaceuticals, Inc. (RXRX) Q1 2026 Earnings Call Transcript
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates
08:45am, Wednesday, 06'th May 2026
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.5 per share a year ago.
Recursion Reports First Quarter Financial Results and Provides Business Update
06:30am, Wednesday, 06'th May 2026
SALT LAKE CITY, May 06, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates highligh
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts
06:45pm, Friday, 01'st May 2026
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.41, indicating a -1.45% shift from the previous trading day.
Recursion Announces Board Transition
04:30pm, Thursday, 30'th Apr 2026
Salt Lake City, UT, April 30, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson
Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6
07:59am, Wednesday, 29'th Apr 2026
Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST
Recursion Pharmaceuticals May Be Losing Ground To Its Peers
08:16pm, Monday, 27'th Apr 2026
Recursion Pharmaceuticals, Inc. remains a Hold as competitive risks persist and the company is years away from meaningful pipeline revenue. RXRX's AI-driven Recursion OS platform shows strong potentia
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market
06:51pm, Thursday, 23'rd Apr 2026
Recursion Pharmaceuticals (RXRX) reached $3.5 at the closing of the latest trading day, reflecting a -6.17% change compared to its last close.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
01:41am, Friday, 17'th Apr 2026
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
06:51pm, Thursday, 16'th Apr 2026
Recursion Pharmaceuticals (RXRX) closed at $3.6 in the latest trading session, marking a -4% move from the prior day.
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
06:50pm, Thursday, 09'th Apr 2026
Recursion Pharmaceuticals (RXRX) closed at $3.32 in the latest trading session, marking a -2.06% move from the prior day.
Recursion to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 07'th Apr 2026
Salt Lake City, April 07, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in
Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know
06:50pm, Thursday, 02'nd Apr 2026
Recursion Pharmaceuticals (RXRX) reached $3.11 at the closing of the latest trading day, reflecting a +1.63% change compared to its last close.
1 Beaten-Down AI Stock to Buy and 1 to Avoid
07:45am, Wednesday, 01'st Apr 2026
One of these is not like the other.
Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform
09:00am, Tuesday, 31'st Mar 2026
Citeline, a leader in clinical solutions for the life sciences, announced an expanded strategic partnership with Recursion, a leading tech-bio company.
